Conference Coverage

ZO-FAST: Immediate Zoledronic Acid Beats Delayed Tx in Early Breast Cancer

Publish date: December 8, 2011

 

FROM THE SAN ANTONIO BREAST CANCER SYMPOSIUM

Dr. de Boer is on the speakers’ bureau for Novartis. Dr. Ingle said he had no financial conflicts to disclose.

Pages

Recommended Reading

Long-Term Risk of GI Cancers Not Elevated in Celiac Patients
MDedge Family Medicine
BOLERO-2: Everolimus Plus Exemestane Delays Breast Cancer Progression
MDedge Family Medicine
Breast Cancer Gene Profile Identifies Early vs. Late Recurrences
MDedge Family Medicine
Zoledronic Acid's Breast Cancer Benefit Extends 7 Years
MDedge Family Medicine
IOM Dissects Environmental Risk Factors for Breast Cancer
MDedge Family Medicine
Dual HER2 Blockade Defers Breast Cancer Progression
MDedge Family Medicine
DCIS Assay Predicts Recurrence Risk After Breast Surgery
MDedge Family Medicine
Clodronate Offered Modest Benefit for Breast Cancer Patients
MDedge Family Medicine
Panel Endorses Surveillance for Low-Risk Prostate Cancer
MDedge Family Medicine
Medicare Study Confirms Colonoscopy's Cancer Prevention Power
MDedge Family Medicine